Skip to Content

Sorafenib Pregnancy and Breastfeeding Warnings

Sorafenib is also known as: Nexavar

Sorafenib Pregnancy Warnings

Animal studies have revealed evidence of embryotoxicity, fetolethality, and teratogenicity. There are no controlled data in human pregnancy. The manufacturer states that based on the proposed mechanism of multikinase inhibition and multiple adverse effects seen in animals at exposure levels significantly below the clinical dose, sorafenib should be assumed to cause fetal harm when administered to a pregnant women.

FDA pregnancy category: D

Use of sorafenib should be avoided.

Instruct both men and women of childbearing potential to use effective birth control during treatment with sorafenib and for at least 2 weeks after stopping treatment.

See references

Sorafenib Breastfeeding Warnings

Women should be advised against breast-feeding while receiving sorafenib.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.

References for breastfeeding information

  1. "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide